

1 **Title:**

2 Long-term and low-level envelope C2V3 stimulation from highly diverse virus isolates leads to
3 frequent development of broad and elite antibody neutralization in HIV-1 infected individuals

4

5 Francisco Martin¹, José Maria Marcelino^{1,2}, Claudia Palladino¹, Inês Bárto¹, Susana Tracana¹,
6 Inês Moranguinho¹, Paloma Gonçalves¹, Rita Mateus¹, Rita Calado¹, Pedro Borrego¹, Thomas
7 Leitner³, Sofia Clemente⁴, Nuno Taveira^{1,2#}

8

9 ¹Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa,
10 Lisbon, Portugal; ²Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto
11 Universitário Saúde Egas Moniz, Caparica, Portugal; ³Theoretical Biology and Biophysics Group,
12 Los Alamos National Laboratory, Los Alamos, NM 87545, USA; ⁴Hospital da Divina Providência,
13 Luanda, Angola.

14

15 **Running Head:** Antibody neutralization and HIV-1 evolution

16 # Address correspondence to:

17 Nuno Taveira

18 Research Institute for Medicines (iMed.Ulisboa),

19 Faculty of Pharmacy, Universidade de Lisboa

20 Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal

21 Email: ntaveira@ff.ul.pt

22 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abstract**

24 Elicitation of potent neutralizing antibodies against genetically diverse HIV-1 isolates is
25 important for an effective HIV-1 vaccine. Some HIV-1 infected patients produce such broadly
26 neutralizing antibodies (bNAbs). Identification of host and viral correlates of bNAb production
27 may help develop the next generation of HIV-1 vaccines. We carried out the first detailed
28 characterization of the neutralizing antibody response and identify viral and host factors
29 associated with the development of bNAbs in HIV-1 infected patients from Angola, one of the
30 oldest, more dynamic, and diverse HIV-1 epidemics in the world. Plasma samples from 322 HIV-
31 1 infected patients were collected in 2001, 2009 and 2014. Phylogenetic analysis of C2V3C3
32 envelope sequences identified a diverse array of subtypes including A1, A2, B, C, D, F1, G, H, J,
33 untypable strains, and recombinant forms which prevailed over pure subtypes. Notably, 56% of
34 the patients developed cross, broad, or elite neutralizing responses against a reference panel of
35 tier 2 Env-pseudoviruses far exceeding results obtained elsewhere in the world. The frequency
36 of elite neutralizers was higher in 2014, when patients were on ART and had low viremia, than
37 in 2009 when patients were drug naïve. In drug naïve patients, broad neutralization was
38 associated with subtype C infection, lower CD4+ T cell counts, higher age, or higher titer of
39 C2V3C3-specific antibodies relative to patients that did not develop bNAbs. Neutralizing
40 antibodies targeted the V3-glycan supersite in most patients but antibodies specific for the V2
41 apex, the CD4 binding site, the gp41 membrane-proximal external region (MPER) and unknown
42 epitopes were also found in some patients. V3 and C3 regions were significantly less variable
43 and less subject to positive selection in elite neutralizers compared to weak or no neutralizers
44 suggesting an active role of bNabs directed against these regions in controlling HIV-1 replication
45 and diversification. Hence, development of broad and elite antibody neutralization against HIV-
46 1 requires long-term and low-level envelope V3C3 stimulation from highly diverse subtype C
47 isolates. These results have direct implications for the design of a new generation of HIV-1
48 vaccines.

49 Introduction

50 The HIV-1 Env glycoprotein is highly immunogenic but, in general, the antibodies elicited by it
51 during infection lack neutralizing breadth or potency against primary HIV-1 strains thus failing
52 to inhibit viral replication in infected individuals^{1,2}. In natural infection only 5% to 30% of adults
53 develop broadly neutralizing antibodies (bNAbs) after several years of infection^{2, 3, 4, 5, 6, 7} and
54 these bNAbs have little impact in the control of the infection due to the continuous capacity of
55 HIV-1 to diversify and escape these antibodies^{5,8,9}. However, some recombinant human bNAbs
56 suppress viral replication in HIV-1 infected individuals^{10, 11, 12, 13, 14, 15}, prevent human infection by
57 some HIV-1 strains¹⁶, and passive immunization in animal models can protect from infection
58 and/or disease progression (reviewed in¹⁷). Therefore, bNAbs are promising tools to restrict
59 HIV-1 transmission and control disease progression if they could be induced by vaccination.
60 Unfortunately, so far, antibodies elicited by candidate immunogens and vaccines have shown a
61 limited ability to neutralize heterologous primary HIV-1 strains^{8, 18, 19, 20, 21, 22, 23, 24}.

62 bNAbs target five highly conserved epitopes in the HIV-1 envelope: the CD4 binding site (CD4bs);
63 the V2 apex; V3 glycan supersite; gp41 MPER, and gp41/gp120 interface which includes the
64 fusion peptide^{17, 25, 26}. However, the mechanisms underlying the elicitation of such antibodies
65 by B cell populations are still largely unknown^{27, 28, 29, 30}. Guiding the immune system to elicit
66 such bNAbs remains a major challenge due to the extremely complex antibody maturation
67 pathways and high levels of somatic hypermutation required by HIV-1 specific antibodies to
68 acquire neutralization breadth^{30, 31}. An exception is the V3-glycan supersite bNAb lineage that
69 does not require extensive antibody-affinity maturation^{32, 33} allowing their development in early
70 stages of infection³⁴, and explaining their high prevalence in recently infected individuals³.
71 Furthermore, V3-specific IgG binding and neutralizing responses in pregnant woman living with
72 HIV-1 predict low risk of mother-to-child-transmission of the virus³⁵. In HIV-2 infected
73 individuals, the V3 loop is a dominant target of bNAbs such that V3 undergoes extensive

74 sequence, conformational and functional alterations to escape antibody neutralization ^{36, 37, 38}.

75 Such findings, together with the proved therapeutic value of V3-glycan supersite bNAbs ¹²,

76 highlight this epitope as a key target for HIV vaccine design.

77 Understanding the mechanisms underlying the production of bNAbs against HIV-1 in some

78 individuals during natural infection is of crucial importance for the development of improved

79 immunogens and immunization strategies. Gray et al. ³⁹ showed that patients infected with HIV-

80 1 clade C rarely produce antibodies binding to the 2F5 neutralizing epitope in gp41 suggesting a

81 correlation between HIV-1 subtype and neutralizing response. However, other studies found

82 limited to no impact of HIV-1 subtype in plasma neutralization, suggesting that HIV-1 group M

83 subtypes and neutralization response evolved independently ^{5, 40, 41}. More recently, in a large

84 longitudinal Sub-Saharan HIV primary infection cohort, cross-clade plasma neutralization was

85 strongly correlated with subtype C infection ³. Additionally, Rusert et al. ² found a strong

86 association between plasma neutralization specificity and HIV-1 subtype, with subtype B viruses

87 being more vulnerable to CD4-binding-site specific antibodies and non-B viruses being more

88 vulnerable to V2-glycan specific neutralizing antibodies. In this study, V3-glycan and MPER-

89 specific neutralizing responses were independent of viral subtype. The differences observed

90 between studies might be related with the different assay conditions used to assess neutralizing

91 activity, in particular with the selected indicator virus panel that should represent the global HIV-

92 1 diversity and be standardized to allow inter-study comparison ⁴².

93 Considering that vaccine effectiveness will depend on the extent to which induced antibodies

94 will neutralize the global diversity of circulating HIV-1 variants, it is important to characterize

95 HIV-1 antibody responses in different epidemics and geographies. For example, we recently

96 showed that the frequency and level of antibody response to selected epitopes in the envelope

97 gp41 differ between HIV-1 infected patients from Germany, France, and Portugal which have

98 different subtype distribution ⁴³. In Switzerland, data analysis of the Swiss HIV Cohort reported

99 that ethnicity was associated with bnAb induction being black participants more prone to
100 develop bNAb responses ².

101 The neutralizing antibody response of HIV-1 infected patients from Angola has never been
102 evaluated. Angolan HIV-1 epidemic is peculiar, as it is driven by all subtypes, multiple circulatory
103 recombinant forms (CRFs) and unique recombinant forms (URFs) ^{44, 45, 46, 47}. In addition, being a
104 very old epidemic, highly divergent and ancestral forms of the different subtypes are often
105 present ^{45, 47, 48, 49}. It has been suggested that the genetic complexity of the virus quasispecies
106 present in HIV-1 individuals is directly related to the development of neutralization breadth
107 regardless of infection duration (reviewed in ⁵⁰). This should be particularly evident in old
108 epidemics such as the one of Angola. Hence, characterizing the antibody responses and HIV-1
109 evolution in this population may provide new insights into the development and evolution of
110 the neutralizing antibody response against HIV-1 and into vaccine design. Here, we carried out
111 the first detailed characterization of the neutralizing antibody response against HIV-1 in Angola
112 and identified viral and host factors associated with the neutralizing response.

113

114 **Materials and Methods**

115 **Study population and ethics statement**

116 This cross-sectional retrospective study included 322 HIV-1 infected adults. Plasma samples
117 were collected in 2001, 2009 and 2014 at the Hospital da Divina Providência (HDP), a referral
118 hospital in Luanda, the capital city of Angola. Eligible participants had ≥19 years of age, were not
119 pregnant and had a serological diagnosis of HIV-1 [Determine HIV-1/2 (Abbott) and Uni-Gold
120 Recombigen (Trinity Biotech) rapid tests]. Plasma viral load and number of CD4+ T cells were
121 determined in a subset of patients using the Abbott Real Time HIV-1 assay (Abbott Laboratories)
122 and the ABACUS 5 Junior Hematology analyser, respectively. The study was conducted according
123 to the Declaration of Helsinki and was reviewed and approved by the National Ethics Committee

124 of Angola. The study was verbally explained to all the patients before obtaining their written
125 consent.

126 **Cell lines**

127 TZM-bl and HEK-293T cell lines were obtained from the NIH AIDS Reagent Program
128 (<https://www.niaid.nih.gov/research/nih-aids-reagent-program>). TZM-bl cells were engineered
129 from HeLa cells that constitutively express CXCR4 to express large amounts of CD4, CCR5 and a
130 firefly luciferase reporter gene under the control of the HIV-1 LTR⁵¹. Cells were cultured at 37°C,
131 5% CO₂ using Dulbecco minimal essential medium (DMEM) supplemented with 10 % heat-
132 inactivated fetal bovine serum and with 100 units/ml of penicillin and 100 µg/ml of
133 streptomycin.

134 **Viral RNA extraction, PCR amplification, sequencing, and phylogenetic analysis**

135 Before viral RNA extraction, 1 ml of plasma was centrifuged at 35,000rpm (61,793g) for 1h at
136 4°C to concentrate viral particles. Supernatant was stored at -80°C for other applications and
137 pelleted material was resuspended with 560 µl of Buffer AVL+RNA carrier from the QIAmp® Viral
138 RNA Mini Kit (Qiagen) and the manufacturer's protocol was followed. Reverse transcription was
139 performed with NZY First-Strand cDNA Synthesis Kit (NZYtech, Portugal) and a 534bp fragment
140 comprising the C2V3C3 *env* region was amplified by PCR using an in-house method described
141 elsewhere^{47, 52}. Sequencing of the C2V3C3 amplicons was performed with BigDye Terminator
142 Cycle Sequencing Kit (Applied Biosystems). Sequences were aligned with reference strains
143 collected from the Los Alamos HIV Sequence Database (<http://www.hiv.lanl.gov/>) using Muscle
144 in MEGA version 6 software⁵³. Maximum-likelihood (ML) phylogenetic analyses were performed
145 using the best-fit model of nucleotide substitution as estimated by Modeltest v3.7 under the
146 Akaike information criterion⁵⁴. ML trees were inferred with PhyML 3.0⁵⁵. Tree searching was
147 done with nearest neighbour interchange and subtree pruning and regrafting. The reliability of
148 the obtained topology was estimated with bootstrap with 500 replicates⁵⁵.

149 Determination of coreceptor usage was made based on the V3 loop sequence using geno2pheno
150 [coreceptor] webtool (<https://coreceptor.geno2pheno.org/>)⁵⁶. False positive rates (FPR) were
151 10% as recommended⁵⁷.

152 Selective pressure was examined with the DATAMONKEY web-server
153 (<https://www.datamonkey.org/>)⁵⁸, after removing all positions containing gaps and missing
154 data from the dataset. All estimations were performed using the MG94 codon substitution
155 model crossed with the nucleotide substitution model GTR previously selected with Modeltest.
156 Four different approaches were used to identify codons under selection: single-likelihood
157 ancestor counting (SLAC), fixed-effects likelihood (FEL), internal fixed effects likelihood (IFEL)
158 and relaxed-effects likelihood (REL) methods⁵⁹. While SLAC, FEL and REL detect sites under
159 selection at the external branches of the phylogenetic tree, IFEL identifies such sites only along
160 the internal branches. To classify a site as positively or negatively selected the cut-off P-value
161 was 10% for SLAC, FEL and IFEL. For REL, codons under selection were detected with a cut-off
162 value for the Bayes factor of 50.

163 **Entropy and N-linked glycosylation analysis**

164 Potential N-linked glycosylation sites were identified using the N-Glycosite software⁶⁰, and the
165 entropy at each amino acid position was measured with Shannon's entropy-one and Shannon's
166 entropy-two online tools, all available at the Los Alamos National Laboratory HIV sequence
167 database (<http://www.hiv.lanl.gov/>).

168 **Production of C2V3C3 polypeptides and analysis of antibody reactivity**

169 Six 178 amino acids long polypeptides comprising part of C2, V3 and part of C3 envelope regions
170 (position 212–390 in gp120 in HIV-1 HXB2) of HIV-1 isolates circulating in Angola (subtypes C,
171 G, H, J, and CRF02_AG) and Portugal (subtype B) were expressed in *Escherichia coli* and purified
172 as described previously⁶¹. Briefly, a DNA fragment of 534 nucleotides comprising the C2, V3 and
173 C3 coding regions (position 6858-7392 in HIV-1 HXB2) was amplified from plasmids containing

174 the full-length envelope gene using the primers described elsewhere and cloned into the
175 bacterial expression vector pTrcHis (Invitrogen)⁶¹. Expression of C2V3C3 polypeptides in
176 *Escherichia coli* strain TOP10 was induced with isopropyl- β -D-thiogalactopyranoside (IPTG)
177 according to the manufacturer's instructions, and protein purification was performed using
178 Dynabeads[®] His-tag Isolation & Pulldown (Life Technologies). Bradford assay (Bio-Rad) was
179 performed to determine protein concentration. Purified recombinant polypeptides were
180 analysed by SDS-12% PAGE.

181 Antibody reactivity against these polypeptides was determined using an ELISA assay as
182 described⁶¹. In brief, 96-wells ELISA plates were coated overnight at 4°C with 100 μ l of 0.05M
183 bicarbonate-coating buffer (pH=9.4) containing 100 ng of the different C2V3C3 polypeptides.
184 Plates were blocked with 2% gelatine in Tris-buffered saline (TBS) 1X for 1h at room
185 temperature. Serial dilutions of plasma (1:100 to 1:3200) in primary antibody buffer (TBS 1X +
186 0.05 % Tween 20 + 5 % blocking solution) were added to the wells and the plates were incubated
187 for 2h at room temperature. Goat anti-human IgG conjugated to alkaline phosphatase, diluted
188 1:2000 in the primary antibody buffer and 5% goat serum was added to the wells. Plates were
189 washed between steps with TBSt (TBS 1X + 0.05 % Tween 20). Plates were developed by adding
190 Sigma-fast p-nitrophenol phosphate diluted in deionized water. The plates were incubated for
191 20 minutes at room temperature protected from light. Optical density (OD) was read at 405nm
192 on a microplate reader. The clinical cut-off value of the assay was calculated as the mean OD
193 value of HIV-seronegative samples plus two times the standard deviation (SD). Binding antibody
194 titers were calculated as the highest plasma dilutions giving a positive reaction (OD / cut-off > 1).

195 **Production of Env-pseudotyped viruses**

196 A reference panel of 12 tier 2 HIV-1 Env-pseudotyped viruses of subtypes C (n=3), A (n=1),
197 CRF07_BC (n=2), CRF01_AE (n=2), B (n=2), G (n=1) and AC recombinant (n=1) were produced
198 using the Global panel of HIV-1 Env clones⁴², obtained through the NIH AIDS reagent program.

199 Env-pseudotyped viruses were produced by transfection of Env-expressing plasmids in 293T
200 cells using pSG3.1Δenv as backbone, in a 1:3 ratio using JetPRIME® DNA transfection reagent.
201 Viral stocks were filtered through 0.45 μm pore size filters after 48 hours and stored at -80°C
202 until use.

203 **Plasma neutralization assay**

204 Neutralization of the Env-pseudotyped viruses was assessed in TZM-bl cells using Tat-induced
205 luciferase (Luc) reporter gene expression to quantify the reduction in virus infection as described
206 previously ⁶². Briefly, TZM-bl cells (10,000 cells/well) were seeded the day before the
207 neutralization assay to allow adherence of the cells to the bottom of the wells. Heat inactivated
208 plasma samples (56°C for 30 min) were incubated at 1:40 dilution in triplicate with the respective
209 Env-pseudotyped virus for 1 hr at 37°C before transfer to TZM-bl cells. After 48 hours, percent
210 neutralization was determined by calculating the difference in average relative light units (RLU)
211 between test wells containing plasma samples and the wells containing the Env-pseudotyped
212 virus from the indicator panel after the normalization of the results using the average RLU of cell
213 control wells. Results were considered valid if the average RLU of virus wells was >10 times the
214 average RLU of cell control wells. A virus pseudotyped with the envelope glycoprotein of
215 vesicular stomatitis virus (VSV-G) was used as neutralization specificity control.

216 Neutralizing antibody titers were determined for a subset of plasma samples with known
217 antibody profiles (n=64). In this case, 100 μL of 2-fold serial dilutions beginning at 1:40 were
218 mixed with 100 μL of each virus (200 TCID₅₀/well) and incubated for 1 h before adding to the
219 cells. After 48 h, culture medium was removed from each well, and plates were analyzed for
220 luciferase activity as described above. Wells with medium were used as background control, and
221 virus-cell wells were included as infection control. Neutralizing titer (ID₅₀) was defined as the
222 highest dilution for which 50% neutralization was achieved.

223

224 **Neutralization score and plasma categorization**

225 To categorize the neutralizing activity of the Angolan samples in terms of potency and breadth
226 we used a previously described scoring system ^{2, 43, 63}. A score of 0 was attributed when
227 neutralizing activity against a given virus of the panel was less than 20%, a score of 1 when
228 neutralization ranged between 20 and <50%, a score of 2 for 50 to <80% neutralization and a
229 score of 3 for $\geq 80\%$ neutralization. The overall neutralization score (NS) for a given plasma was
230 obtained by adding the scores against the 12 Env-pseudoviruses of the panel and reflects
231 neutralization potency and breadth. As a validated and worldwide accepted classification system
232 to define neutralizing activity is lacking, for the purpose of the present study we classified
233 plasmas with scores 25-36 as elite neutralizers, 18-24 as broad neutralizers, 6-17 as cross
234 neutralizers and < 6 as weak or no neutralizers. According to this classification a plasma sample
235 from an elite neutralizer must neutralize ≥ 9 viruses of the panel with a neutralization potency
236 $\geq 80\%$.

237 **Prediction of bNAbs epitope specificities by clustering analysis**

238 The neutralizing antibody specificities were determined for a subset of patients exhibiting broad
239 and elite neutralization capacity using clustering analysis with human bNAbs targeting the main
240 neutralizing epitopes on the viral envelope and capable to neutralize at least half of the 12 Env-
241 pseudotyped viruses of the panel, as described previously ⁴². Neutralization heatmaps and
242 clusters were computed via the online tool ClustVis using a predefined correlation clustering
243 distance method (Pearson correlation subtracted from 1) based on the average distance of all
244 possible pairs. ClustVis is a web tool for visualizing clustering of multivariate data (available at
245 <https://biit.cs.ut.ee/clustvis/>) ⁶⁴.

246 **Statistical analysis**

247 Statistical analysis was performed with GraphPad Prism versions 5.01 or 9.0 (GraphPad Software
248 Incorporated, San Diego, California, USA). The Mann-Whitney, Kruskal-Wallis or Fisher's exact

249 tests were used to compare differences between groups. The Spearman rank test was used to
250 quantify the magnitude and direction of the correlation between antibody neutralization activity
251 and plasma binding titers against C2V3C3- polypeptides, CD4+ T cell counts, viral subtype and
252 age of patients. Hypothesis tests were two-tailed and P values <0.05 were considered significant.
253 To test the potential correlation between neutralization score and genetic distance of the clinical
254 samples to the neutralization panel viruses, we used amino acid sequences and Hamming
255 distances that included gaps as characters because: 1) neutralization occurs on the amino acid
256 level, 2) does not depend on the evolutionary path to a state-combination, and 3) indels may
257 have significant effects on antibody binding. Genetic distances were calculated using DECIPHER
258 ⁶⁵, regression analysis was performed using R version R-4.0.3 ⁶⁶, and visualization using
259 ggplot2⁶⁷.

260

261 **Results**

262 **Characterization of the study population and infecting HIV-1 isolates**

263 Overall, 375 plasma samples from 322 adult HIV-1 infected patients from three sampling years,
264 2001 (n=106), 2009 (n=210) and 2014 (n=59), were included in this analysis. Epidemiological,
265 clinical, demographic, and virological characterization of the patients is described in **Table S1**.
266 The median age of the patients was 34 years and most (n=242, 64.5%) were women. The main
267 route of transmission was heterosexual contact (n=304, 81.1%). There were no significant
268 differences related to age and sex between sampling years. The median plasma viral load (VL)
269 at the time of sampling was significantly higher in 2001 relative to 2009 (4.2-fold higher) and
270 2014 (33.5-fold higher). The median number of CD4+ T cells in 2014 was 1.8-fold higher when
271 compared to 2009 ($p=0.0015$). The significantly lower VL and higher CD4+ T cell number in 2014
272 is consistent with most patients being on cART which was not the case in 2001 and 2009.

273 Sequencing and phylogenetic analysis of the C2V3C3 Env region was completed successfully for
274 206 patients from 2001 (n=96/106, 90.6%) and 2009 (n=110/210, 52.4%). The following
275 subtypes were identified: A1 (2001, n=33, 34.4%; 2009, n=32, 29.1%), A2 (2001, n=6, 6.3%; 2009,
276 n=3, 2.7%), B (2001, n=2, 2.1%; 2009, n=2, 1.8%), C (2001, n=12, 12.5%; 2009, n=30, 27.3%), D
277 (2001, n=2, 2.1%; 2009, n=8, 7.3%), F1 (2001, n=5, 5.2%; 2009, n=6, 5.5%), G (2001, n=8, 8.3%;
278 2009, n=11, 10%), H (2001, n=19, 19.8%; 2009, n=15, 13.6%), and J (2001, n=3, 3.1%; 2009, n=0,
279 0.0%). Untypable U strains were 4.2% (n=6) in 2001 and 2.7% (n=3) in 2009 (**Figure S1**). Subtype
280 A prevailed in 2001 and 2009, but subtype C increased significantly (2.2-fold, $P=0.0095$) in 2009.
281 Out of the 176 isolates for which there were protease (PR) and C2V3C3 sequences available, 74
282 (42.0%) were non-recombinant and 102 (58.0%) were recombinant. Recombinant strains
283 prevailed over pure subtypes in 2001 and 2009 (**Table S2**).


284 The genotypic analysis showed that most viruses were CCR5-tropic in 2001 (82.3%, N=79) and
285 in 2009 (85.5%, N=94), without significant differences between sampling years (**Figure S2**).
286 Unfortunately, we could not sequence the C2V3C3 region from most of the 2014 samples due
287 to their low or undetectable viral load (**Table S1**). Moreover, the lack of plasma prevented
288 further analysis in samples collected in 2001.

289

290 **Characterization of the antibody response**

291 A total of 236 plasma samples, 178 from 2009 and 58 from 2014, were screened for
292 neutralization breadth and potency against the 12 Env-pseudotyped indicator panel, amounting
293 to 2832 plasma/virus combinations (**Figure S3**). In 2009, 80.9% (144/178) of Angolan patients
294 effectively neutralized at least one virus from the indicator panel; this increased to 93.1%
295 (54/58) in 2014 (**Figure 1**). Likewise, the mean percent neutralization (27.43%, 95%CI: 25.94,
296 28.92 in 2009 vs 60.52%, 95%CI: 57.37, 63.66 in 2014, $p<0.0001$) and the mean neutralization

297 breadth (4.39, 95%CI: 3.83, 4.95 in 2009 vs 8.40, 95%CI: 7.32, 9.48 in 2014, $p < 0.0001$) were
298 higher in 2014 relative to 2009.



300

301 **Figure 1**– Neutralization potency and breadth per sampling year. A) Potency of neutralization (%
302 neutralization at 1:40 plasma dilution) of samples collected in 2009 and 2014 as assessed against
303 the 12-Env-pseudotyped virus indicator panel. Mean and 95% confidence intervals are shown.
304 B) Neutralization breadth (number of Env-pseudotyped viruses neutralized >20%) in samples
305 collected in 2009 and 2014. Median and interquartile range are shown P values were obtained
306 using the Mann Whitney U test.

307

308 The percent neutralization for each plasma-virus combination was recorded as a breadth-
309 potency matrix: $\geq 80\%$ neutralization received a score of 3, 50% to $< 80\%$ a score of 2, 20% to
310 $< 50\%$ a score of 1, and $< 20\%$ received a score of 0. Plasma samples were then ranked by the sum
311 of scores in order to reflect their potency and breadth^{2,63}. Breadth, potency, and neutralization
312 score were directly correlated as expected (**Figure S4**).


313 Mean NS was 11.71, 95% CI [10.22, 13.19] ranging from 0 to 36 and median was 7, IQR [2.0,
314 21.0]. Remarkably, approximately 30% (n= 68/236) of the patients developed antibody
315 responses with the capacity to potently neutralize at least half the viruses from the panel (**Figure**
316 **2A**). Overall, considering both sampling years, 18.6% (n= 44/236) of study participants were elite
317 neutralizers (NS \geq 25), 10.2% (n= 24/236) were broad neutralizers ($18 \leq$ NS < 25), 27.1% (n=
318 64/236) were cross neutralizers ($6 \leq$ NS < 17), and 44.1% (n= 104/236) were weak neutralizers
319 or did not neutralize any virus of the panel (**Figure 2B**).

320


321 **Correlates of the neutralizing response**

322 The neutralizing antibody response has been previously associated with viral load, CD4+ T cell
323 count, viral diversity and infection time^{2,3}. We first analyzed the impact of sample collection
324 time on the neutralizing antibody responses of the HIV infected Angolan patients. Strikingly,
325 median NS was 6.2-fold higher in 2014 relative to 2009 (31.00, IQR [10.50, 33.00] vs 5.00, IQR
326 [1.00, 13.25], $p < 0.0001$) (**Figure 2A**). Consistent with this, the frequency of elite neutralizers was
327 9.5-fold higher in 2014 than in 2009 [57% (n=33/58) vs 6% (n= 11/178), $p < 0.0001$], and weak or
328 no neutralizers were 2.7-fold more frequent in 2009 than in 2014 [52% (n= 93/178) vs 19.0% (n=
329 11/58), $p < 0.0001$] (**Figure 2B**). Broad neutralizers were 2.4-fold more frequent in 2009 than in
330 2014 [12% (n= 21/178) vs 5% (n= 3/58), $p = 0.2107$] and a similar trend was observed for cross
331 neutralizers [30% (n= 53/179) vs 19.0% (n= 11/58), $p = 0.1270$]. We also analysed matching
332 plasma pairs from 2009 and 2014 to determine the evolution of neutralizing antibody response
333 as a function of infection time. In line with the previous results, neutralizing score increased in
334 2014 relative to 2009 in 31 out of the 38 matched plasma pairs analysed (81.6%). (**Figure 2C**).
335 The NS was unrelated with the sex of the patients (**Figure 2D**).


336 A)




B)



C)



D)



337 **Figure 2-** Neutralization score (NS) in HIV-1 infected patients from Angola as a function of year
338 of sampling and sex. A) NS in 2009 is represented in blue and in 2014 in red; NS in all patients is
339 in green. B) Angolan patients were categorized into 4 groups according to the NS as follows: no
340 or weak neutralizers, <6 (grey); Cross neutralizers, 6-17 (yellow); Broad neutralizers, 18-24
341 (orange); Elite neutralizers, 25-36 (red). C) Neutralization score in matched samples collected in
342 2009 and 2014, showing the NS categories. D) NS in males and females. Median and interquartile
343 range are shown. P values were obtained using the Mann Whitney U test.


344

345 The 50% neutralization titers (ID_{50}) against the 12 Env-pseudotyped virus indicator panel were
346 determined in a subset of plasma samples from 2009 (n=28) and 2014 (n=10) showing broad
347 and elite neutralizing activity (**Figure 3A**). When comparing unmatched samples, neutralization
348 titers were significantly higher in 2014 than in 2009 [median $\log_{10} ID_{50}$ in 2009= 1.903, IQ: 1.602-
349 2.505 (n=336 plasma-virus pairs) vs median $\log_{10} ID_{50}$ in 2014= 2.204, IQ: 1.903- 2.806 (n= 120
350 plasma-virus pairs), $p=0.0013$] (**Figure 3A/B**).

A)

Year	ID	Clade	Number of CD4+ T cells/ μ l	HIV-1 Clade											VSV	NS			
				C			A	G	AC		AE		B				BC		
				25710	CE0217	CE1176	398F1	1632	246F3	CNE8	CNE55	TRO11	X2278	X2000			CHI19		
2009 (n=28)	33	F1	208	160	<40	40	80	40	40	80	<40	40	320	<40	40	<40	21		
	43	G	NA	80	<40	80	80	<40	80	160	<40	40	<40	<40	40	<40	18		
	53	C	NA	640	<40	1280	160	80	320	<40	320	<40	<40	160	320	<40	24		
	54	F1	239	160	80	640	80	80	80	<40	<40	<40	40	160	320	<40	27		
	61	C	109	640	640	640	2560	640	1280	<40	1280	640	320	2560	1280	<40	33		
	72	A1	270	160	<40	<40	2560	<40	640	<40	<40	80	<40	40	<40	<40	19		
	77	C	86	160	40	40	80	80	40	40	<40	40	320	40	40	<40	25		
	103	C	181	80	40	40	40	<40	320	1280	80	40	40	40	160	<40	30		
	104	ND	NA	40	<40	80	160	80	80	<40	40	<40	<40	40	160	<40	24		
	122	H	NA	640	40	1280	40	40	<40	<40	80	80	<40	160	<40	<40	21		
	125	G	306	640	40	640	40	80	80	640	<40	<40	80	<40	160	<40	17		
	131	F1	272	320	40	640	<40	40	40	160	<40	<40	40	80	640	<40	24		
	137	C	NA	80	80	40	80	40	80	320	80	40	80	<40	160	<40	29		
	143	C	359	40	40	80	1280	40	80	80	<40	80	160	40	80	<40	28		
	153	H	585	40	40	<40	640	80	<40	40	80	40	320	<40	<40	<40	18		
	169	C	106	80	40	80	640	160	320	320	160	80	160	40	1280	<40	36		
	175	C	488	40	<40	<40	40	80	1280	640	320	80	<40	<40	640	<40	22		
	178	H	125	40	40	<40	<40	40	<40	320	160	160	<40	80	160	<40	25		
	183	D	NA	80	80	40	640	40	1280	640	160	<40	160	<40	80	<40	26		
	184	H	58	80	160	40	<40	80	640	320	160	320	320	80	80	<40	21		
	192	H	248	80	<40	40	160	40	<40	40	<40	<40	320	40	<40	<40	18		
	198	C	737	160	80	160	80	40	80	40	<40	40	80	40	320	<40	23		
	199	G	402	320	40	40	640	<40	<40	40	40	40	80	40	80	<40	20		
	205	C	85	320	40	<40	40	40	40	40	<40	<40	40	40	40	<40	23		
	209	ND	ND	640	40	80	640	40	40	160	40	80	80	<40	80	<40	24		
	278	G	27	80	160	<40	640	160	640	160	640	160	640	ND	<40	160	160	<40	27
	279	H	NA	1280	640	1280	640	40	1280	80	640	ND	640	320	640	<40	32		
	293	G	234	40	<40	<40	40	40	<40	<40	1280	ND	40	<40	640	<40	21		
2014 (n=10)	1	ND	555	40	320	160	1280	40	40	40	80	40	40	40	<40	36			
	21	ND	NA	160	80	80	160	80	<40	80	160	80	160	80	<40	<40	30		
	31	A*	209 [†]	1280	640	1280	2560	1280	1280	1280	640	1280	2560	1280	640	<40	36		
	37	G*	649	320	320	320	1280	40	40	40	640	40	40	40	40	<40	36		
	42	G*	183 [†]	160	40	160	320	160	<40	80	40	80	1280	320	40	<40	27		
	50	C	326	640	160	640	640	640	160	320	160	320	640	640	320	<40	36		
	57	A2*	NA	320	160	160	640	160	160	320	160	320	320	320	160	<40	36		
	143	C	359 [†]	160	<40	80	1280	<40	40	<40	<40	160	160	320	160	<40	26		
165	ND	228 [†]	640	320	320	640	<40	<40	80	<40	40	<40	<40	<40	<40	36			
171	ND	NA	40	<40	<40	40	40	320	160	320	640	<40	320	640	<40	21			

B)



352 **Figure 3-** Antibody neutralization titers in a subset of unmatched plasma samples from elite and
353 broad neutralizers from 2009 (n=28) and 2014 (n=10). A) Heatmap of the neutralization titers
354 (ID50) and neutralization score against the 12 Env-pseudotyped virus indicator panel. ID50
355 values are color-coded, with darker colors implying higher ID50 values. *HIV subtype
356 determined in the pol gene. † Number of CD4+ T cells determined in 2009; ND- not done due to
357 lack of sample; NS- neutralization score; VSV-pseudotyped viruses (neutralization specificity
358 control). B) Comparison of antibody neutralization titers in 2009 and 2014. Log₁₀ ID50 values
359 obtained by each patient sample against the 12 Env-pseudotyped virus indicator panel are
360 plotted. Lines indicate the median with interquartile range. P value was obtained using the Mann
361 Whitney U test.

362 Overall, these results suggest that duration of infection is an important correlate of the potency
363 and breadth of the neutralizing antibody response in Angolan patients infected with HIV-1.


364 To analyse the impact of HIV-1 subtype on neutralization by Angolan samples we compared the
365 neutralization score (NS) in patients infected with subtypes C (n=27) and A1 (n=26), the two
366 prevailing subtypes in Angola, and in patients infected with the other subtypes and recombinant
367 forms (n=56). Only samples collected in 2009 were included in this analysis due to the limited
368 number of samples genotyped in 2014. NS varied significantly with infecting virus subtype
369 ($p=0.014$), with subtype C leading to significantly higher NS than subtype A1 [median NS= 17.00,
370 IQR (6.00, 25.00) vs 6.00 IQR (3.50, 15.00), $p=0.0103$] or other subtypes [median NS= 17.00, IQR
371 (6.00, 25.00) vs 8.00, IQR (1.00, 17.75), $p=0.0087$] (**Figure 4A**). These results indicate that virus
372 subtype is a major determinant of the neutralizing antibody response in our patients.

373 The indicator virus panel used in the neutralization experiments contains three subtype C strains
374 (25710, CE1176, and CE0217) that could be more closely related to the subtype C isolates from
375 the Angolan patients and explain the higher NS observed in patients infected with subtype C
376 viruses. To examine this issue, we compared the susceptibility of the reference panel isolates to
377 neutralization and found a significant variation related to virus subtype (**Figure 4B**). The easiest
378 viruses to neutralize were isolate 25710, a subtype C from India, and 398F1, a subtype A from
379 Tanzania. On the other hand, viruses most resistant to neutralization were 2278, a subtype B
380 from Spain and CNE8, a CRF01_AE from China. Interestingly, subtype C isolates CE1176 and
381 CE0217 from Malawi were significantly more resistant to neutralization than 25710 suggesting
382 a closer relationship of subtype C isolates from Angola to this Indian subtype C isolate and
383 showing that subtype per se is not the main determinant of susceptibility to antibody
384 neutralization. To investigate the impact of the evolutionary distance between the HIV-1
385 Angolan isolates and the indicator virus panel on the neutralizing antibody responses, we aligned
386 the C2V3C3 amino acid sequences from the Angolan isolates (year 2009) with those from the


387 indicator virus panel. As expected, subtype C viruses from the patients were more closely related
388 with subtype C viruses of the indicator panel relative to other subtypes (**Figure S5A**). There was
389 a significant negative correlation of amino acid distance of the indicator panel to NS (Spearman
390 $r = -0.2319$, $p = 0.019$) (**Figure S5B**). Hence, the closer the isolate from the indicator panel was to
391 the patient's C2V3C3 amino acid sequence, the easier it was neutralized. On average, clade C
392 reference strain 25710 from the indicator panel was the closest indicator virus panel member
393 to the Angolan isolates and, not surprisingly, it was the easiest virus to neutralize. At the other
394 end, clade B reference strain 2278 was the furthest away from the C2V3C3 Angolan sequences
395 and was the most difficult virus to neutralize along with the CRF01_AE virus (CNE8).
396 Nevertheless, many patients infected with all subtypes developed potent bNAb responses
397 despite the high genetic distance to the viruses of the indicator panel, indicating that other
398 factors besides the relatedness with the indicator panel contribute to the potency of the
399 neutralizing response.

400

401






402



403 **Figure 4**– Impact of HIV-1 subtype on antibody neutralization. A) Neutralization score in patients
404 infected with the two most common subtypes in Angola (year 2009), C (n=27) and A1 (n=26),
405 and in patients infected with other subtypes and recombinant forms (n=56). The Kruskal-Wallis
406 nonparametric test was used to analyse the difference in median NS for all subtypes ($p=0.014$).
407 Dunns multiple comparison test was used to analyse differences in NS between subtypes.
408 Median and interquartile range are shown. B) Percent neutralization of each of the 12 Env-
409 pseudotyped virus indicator panel by the plasma samples (at 1:40 dilution) from the Angolan
410 patients (N=236). Mean percent neutralization and 95% confidence interval bars against a given
411 virus from the indicator panel are shown. Statistically significant differences are represented by
412 the P values obtained with Dunns multiple comparison test. *** $p<0.0001$, ** $p<0.001$, * $p<0.05$.

413 Drug naïve patients (year 2009) with ≤ 200 CD4+ T cells/ μ l at study entry had significantly higher
414 NS values than patients with > 200 CD4+ T cells/ μ l [median NS in patients ≤ 200 CD4+ T cell counts
415 was 7.00 (IQR, 3.50, 21.00) vs 4.00 (1.00, 12.00) in patients with > 200 CD4+ T cell counts, $p =$
416 0.0193] (**Figure 5A**). Moreover, NS values were inversely associated with CD4+ T cell counts
417 (Spearman $r = -0.3043$, $p = 0.0005$) (**Figure 5B**) and directly associated with age (Spearman
418 $r = 0.1644$, $p = 0.0302$) in these patients (**Figure 5C**). These results suggest that elicitation of high
419 levels of broadly neutralizing antibodies in these patients is directly correlated with prolonged
420 antigenic stimulation⁶⁸.




422 **Figure 5--** Correlation between neutralization score, CD4+ T cell counts and patient's age. A)
423 Neutralization score differences between 2009 patient's with ≤ 200 CD4+ T cell counts at study
424 entry and patients with >200 CD4 T cell counts. Median and interquartile range are shown. P
425 values were obtained using the Mann Whitney U test; B) Correlation of neutralization score with
426 CD4+ T cell counts in 2009 and 2014; C) Correlation of neutralization score with patient's age in
427 2009 and 2014. Samples collected in 2009 are shown in blue and samples collected in 2014 in
428 red. Linear trend is shown with mean and 95% CI bands; Spearman r and P values are indicated.
429

430 **Epitope specificities of the plasma neutralizing antibodies**

431 In the same subset of 38 plasma samples (n=28 from 2009 and n=10 from 2014) from broad and
432 elite neutralizers, the epitope specificities were mapped using a computational clustering tool
433 based on the epitope specificities of a panel of human bNAbs⁶⁴. Six (15.8%) samples did not
434 cluster with any of the bNAbs. Thirty-two (84.2%) samples clustered with one of the bNAbs. Of
435 these most samples (68.8%, 22/32) clustered with PGT128 and 2G12, two bNAbs that target the
436 V3 glycan supersite with important contact residues in V3 and V4 (**Figure 6**)^{69,70}. Five (15.6%)
437 samples clustered with bnAb 4E10 that targets the gp41 membrane-proximal external region
438 (MPER)⁷¹. Four (12.5%) samples clustered with VRC01 and VRC-CH31 bNAbs that target the CD4
439 binding site. Finally, one (3.1%) sample clustered with PG16 and PG9 that target the V1V2
440 glycans. These results indicate that the V3 glycan supersite is the dominant broadly neutralizing
441 epitope in Angolan patients.

442

443



456 **Figure 6- Cluster analysis and heatmap of the predicted epitope specificity in the top**
457 **neutralizing patients from Angola.** In the top of the columns, known bnAb epitopes are coloured
458 according to the respective epitope specificities as shown by the legend. The identification of
459 the plasma samples and bnAbs is shown in the bottom of the columns. Cluster analysis for both
460 rows and columns were computed according to the Pearson correlation ⁶⁴. Blue colours in the
461 heatmap represent lower neutralization activity and red colours higher neutralization activity.
462 Each column represents the neutralization values of a given plasma sample or a bnAb of known
463 specificities against the 12 Env-pseudotyped virus panel whose names are indicated to the left.

464







465 **Neutralization score is directly related with titer of C2V3C3-binding antibodies in all subtypes**

466 The antibody binding reactivity against a panel of recombinant polypeptides comprising the C2,
467 V3, and C3 envelope regions of subtypes B, C, G, H, J, and CRF02_AG was characterized in a
468 subset of samples from 2009 (n=48) and 2014 (n=16) with known antibody neutralization profile.
469 All but the B polypeptide were derived from Angolan isolates. All but six samples from five
470 patients reacted with all C2V3C3 polypeptides demonstrating the high antigenicity of this
471 envelope region (**Figure S6**). In 2009, patients had significantly higher median antibody binding
472 titers against subtype C than against subtypes G ($p=0.0007$), H ($p=0.0282$), J ($p=0.0052$), and
473 CRF02_AG ($p=0.0149$). Of note, median antibody binding titers were always higher in 2014
474 relative to 2009 regardless of the C2V3C3 polypeptide subtype but this was not significant
475 except for CRF02_AG.

476 The higher antibody reactivity against subtype C antigen could be related with the higher
477 neutralizing responses observed in subtype C infected patients. We therefore investigated
478 possible associations between neutralization score, C2V3C3 antibody binding titer and subtype.
479 Remarkably, C2V3C3 antibody binding titer was positively associated with NS values, i.e.,
480 patients with higher antibody binding titers to C2V3C3 polypeptides had higher neutralizing

481 antibody responses (**Figure 7**). This was significant for all subtypes of the C2V3C3 recombinant
482 polypeptides tested confirming this epitope as an important neutralizing domain in these
483 patients independent of subtype.

484



485

486

487 **Figure 7** -Association between antibody binding titer to C2V3C3 recombinant polypeptides of
488 different subtypes and neutralization score (year 2009). Filled symbols are the antibody binding
489 titers of the broad/elite neutralizers to a given C2V3C3 subtype. Unfilled symbols are the
490 antibody binding titers of the no/weak and cross neutralizers to a given C2V3C3 subtype.
491 Associations were assessed by Spearman analyses. P-values and Spearman r values are
492 indicated. Linear trend is shown with mean and 95% CI bands.


493

494 **Impact of the neutralizing antibodies in the diversity and evolution of C2V3C3**


495 Neutralizing antibodies targeting the C2, V3 and C3 envelope regions are common in HIV-1
496 infected individuals³ and escape from these antibodies leads to higher diversity in these regions
497 as well as to higher positive selection and convergent evolution^{72,73,74}. To investigate the impact
498 of the neutralizing antibodies in the diversity and evolution of the envelope glycoproteins of the
499 viruses infecting our patients, we analysed amino acid entropy and the sites under selective
500 pressure in the C2, V3 and C3 regions in the different neutralization categories for samples
501 collected in 2009. Considering the three regions together, mean overall entropy values were
502 similar in all neutralization categories: weak/no neutralizers= 0.5727 [95% confidence interval
503 (CI): 0.4753, 0.6241]; cross neutralizers= 0.5931 (0.5012, 0.6849); broad neutralizers= 0.5381
504 (0.4472, 0.6291); and elite neutralizers= 0.4106 (0.3313, 0.4899). Regardless of neutralization
505 category, the region with higher mean entropy was C3 [0.8528 (0.7556, 0.9500)] followed by V3
506 [0.4659 (0.3903, 0.5414)] and C2 [0.3635 (0.3092, 0.4178)] ($p<0.0001$). We then plotted
507 Shannon's entropy differences in C2V3C3 between no/weak neutralizers and cross, broad and
508 elite neutralizers. This analysis revealed that viruses from elite neutralizers were far less variable
509 than viruses from weak/no neutralizers as seen by the number of amino acids with positive
510 entropy differences relative to amino acids with negative entropy differences (37 vs 16 sites,
511 $p=0.0023$) (**Figure 8**). On the other hand, viruses from broad and cross neutralizers did not vary

512 significantly from viruses from no/weak neutralizers. Relative to no/weak neutralizers, the most
513 variable amino acid residues in the broad and elite neutralizers were found in V3 and/or C3
514 (broad neutralizers: 1 site in C2 vs 7 sites in C3, $p < 0.0001$; elite neutralizers: 3 sites in C2 vs 13
515 sites in V3C3, $p < 0.0001$), two regions that contain broadly neutralizing epitopes (**Figure 8**).


A)



B)



C)



516

517

518 **Figure 8** – Amino acid entropy difference in the C2V3C3 region between neutralization categories. A) Shannon's entropy difference between No/Weak and
519 Cross neutralizers. B) Shannon's entropy difference between No/Weak and Broad neutralizers. C) Shannon's entropy difference between No/Weak and Elite
520 neutralizers. Sites with significant entropy difference ($p \leq 0.05$) are shown in red. Gray boxes delimitate the V3 region. Numbers in the x axes indicate the
521 amino acid position in HIV-1 HXB2.

522 Diversifying selection in C2V3C3 varied according to the different neutralization categories
523 ($p < 0.001$) (**Table S3**). Considering only sites that were selected by at least two methods, weak/no
524 neutralizers had a total of 9 positively selected sites, cross neutralizers 6, broad neutralizers 3
525 and elite neutralizers 1. Regardless of neutralization category most sites under selective
526 pressure were present in the C3 region.

527 The mean number of N-glycosylation sites in C2V3C3 was similar in all neutralization categories
528 [Non-neutralizers: 9.2 (range: 8-12); cross-neutralizers: 9.2 (range: 7-11), broad-neutralizers: 9.4
529 (range: 7-11); elite-neutralizers: 9.8 (range: 8-11)] (**Table S4**). C3 had more potential N-
530 glycosylation sites than C2 or V3 but sites in V3 and C2 were more conserved. For example, sites
531 241, 262, 276 and 289 in C3 were present in $\geq 70\%$ of strains and site 301 in the V3 crown was
532 present in all but two strains (97%). In C3, site 332, which together with site 301 in V3 and other
533 elements in V1, V3 and V4 is part of the V3-glycan supersite^{75,76}, was highly conserved (70%) in
534 all neutralization categories.

535

536 **Discussion**

537 HIV-1 was introduced in Angola from Kinshasa, the capital city of the Democratic Republic of
538 Congo (DRC), likely in 1910-1940 making the Angolan epidemic the second oldest in the world
539⁴⁸. Like in the DRC, the Angolan epidemic has been driven by all subtypes but B, untypable and
540 highly divergent strains, and multiple CRFs and URFs^{44, 45, 46, 47}. In this study we confirmed the
541 extremely high diversity and evolving complexity of HIV-1 strains present in Angola. Subtypes A
542 and C dominated over other subtypes but all other Env subtypes were present along with
543 untypable basal strains and recombinant strains that prevailed over pure subtypes. The
544 remarkable diversity and evolution of HIV-1 in Angola is driven by the increasing number of new
545 infections⁷⁷, the limited access to antiretroviral therapy, and high levels of drug resistance^{46, 78}.

546 The high diversity and rapid evolution of HIV-1 in this country can pose a serious challenge to
547 vaccination and other preventive efforts.

548 At the individual level, the long-term B cell stimulation by this highly diversified ensemble of
549 viruses may have promoted the development of exceptional neutralization breadth^{2, 3, 75, 79, 80, 81,}
550^{82, 83}. We found that the majority (56%) of the patients in our cohort developed cross, broad, or
551 elite neutralizing responses. These results far exceed those from previous cohort studies in sub-
552 Saharan Africa^{3, 63, 79, 84, 85}. For example, Beirnaert *et al.* found 10.6% broad neutralizers in
553 Cameroon⁸⁵ and Landais *et al.* found about 15% broad neutralizers in a cohort of HIV-1 infected
554 patients from Eastern and South Africa³. When compared to cohort studies from other
555 geographies where subtype B dominates, the frequency of patients with bNAbs responses
556 reported in our study was also much higher^{2, 5, 86}. For example, Rusert *et al.*² in Switzerland found
557 that most patients (79.1%) showed weak or no neutralization breadth, which compares to 44%
558 in our cohort, and that only 1.3% were elite neutralizers which compares to 19% in our cohort.
559 This divergence may be related with many factors besides the diversity of infecting viruses, such
560 as the HLA genotype and ethnicity of the patients, viral load, CD4+ T cell counts, and duration of
561 infection^{2, 3, 79, 80, 87}.

562 In agreement with other studies, neutralization score was inversely correlated with CD4+ T cell
563 counts in 2009 when the patients were naïve to ART and had high viral load^{2, 3, 75, 80}. This is
564 generally associated with high envelope stimulation of B cells and inevitably leads to B-cell
565 exhaustion in chronic viraemic HIV-1 infection⁸⁸. Remarkably, however, the frequency of elite
566 neutralizers and the mean neutralization score in matched and unmatched patients increased
567 significantly in 2014, when patients were already undergoing ART, relative to 2009. The boost in
568 the quality of the neutralizing response in these patients suggest good restoration of the B cell
569 compartment with ART which is uncommon in chronic HIV-1 infection^{88, 89, 90}. Moreover, the
570 moderate level of plasma viremia (median 11,660 HIV-1 RNA copies /ml, IQR, 380-30,060) found

571 in these patients may have provided the low-level antigenic stimulation needed for the full
572 maturation of memory B cells and bNAb production^{31, 88, 91}. This has precedent in HIV-2 infection
573 where most patients are infected for long periods and produce potent and broadly neutralizing
574 responses in a setting of low plasma viremia^{36, 92, 93}. In this model, B cell exposure to low-level
575 envelope antigens, likely in lymphoid tissues, during prolonged infection periods leads to the
576 generation of highly specific envelope C2V3C3- specific antibodies as well as broad and potent
577 neutralizing antibodies⁹⁴.

578 Viral type and subtype as well as the nature of the epitope target on the viral envelope impact
579 the antibody maturation process as seen by the frequency of elicitation^{61, 93} and epitope
580 specificity of bnAbs^{2, 50, 76}. Differences in envelope structure and epitope exposure, length of
581 variable loops, type of V3 motifs, N-glycosylation patterns, and conservation of key sites have
582 helped to explain why certain HIV-1 subtypes like subtype C are better at promoting the
583 elicitation of neutralizing antibodies^{2, 3, 50, 61, 76, 84, 95}. In line with these studies, we found that
584 infection with subtype C viruses was associated with enhanced neutralization breadth and
585 potency. In general, subtype C infected individuals have shown a bias to V2-glycan directed
586 antibody responses, and subtype C envelope from transmitted viruses have been less prone to
587 neutralization by V3-directed antibodies due to the absence of the N332- glycan in the C3 region
588^{2, 3, 76, 84, 96, 97, 98}. This was not the case in our study as most top neutralizers had V3-directed
589 antibodies that were able to neutralize the subtype C isolates from the virus panel, and the N301
590 and N332 glycans defining the V3-glycan supersite were highly conserved in the patient's
591 isolates. Supporting the major role of the V3 and C3 envelope regions in the development of
592 bNAbs in our cohort, we found a strong direct correlation between the titer of antibodies
593 binding to C2V3C3 envelope polypeptides from all subtypes and neutralization score.
594 Nonetheless, antibodies specific for the V2 apex, the CD4 binding site, the gp41 MPER and/or
595 unknown epitopes were also found in some patients revealing the complexity of the neutralizing
596 antibody responses in these patients.

597 We also looked at the variability of patient's sequences in the envelope C2V3C3 region to assess
598 the impact of escape from neutralizing antibodies on viral evolution and diversity. V3 and C3
599 were the most variable regions which is consistent with the dominant role of neutralizing
600 antibodies targeting these regions in these patients ³. V3 bNAb recognition sites and sites
601 associated with resistance to neutralization such as N295 ^{3, 75, 80} were under positive selection in
602 broad and elite neutralizers. However, elite neutralizers exhibited far less variability and lower
603 number of sites under selective pressure in V3 and C3 relative to weak or low neutralizers. The
604 convergence of the viral swarm to a few resistant strains provides convincing evidence for the
605 crucial role of V3- and C3-directed bNAbs in controlling HIV-1 replication and diversification in
606 these patients ^{35, 61, 84, 99}.

607 In conclusion, an exceptionally high number of Angolan patients infected with HIV-1 elicits broad
608 and elite neutralizing antibodies mostly targeting the V3-glycan supersite. This is associated with
609 long-term and low-level V3- and C3- antigenic stimulation by the highly diverse isolates
610 circulating in this country especially subtype C. These results have direct implications for the
611 design of a new generation of HIV-1 vaccines.

612

613 **Acknowledgments**

614 We greatly acknowledge the contribution and efforts of the staff and patients from the Hospital
615 da Divina Providência in Luanda for this study. TZM-bl cells were obtained through the NIH AIDS
616 Reagent Program, Division of AIDS, NIAID, NIH. This work was supported by Fundação para a
617 Ciência e a Tecnologia (FCT), Portugal, under project grants UIDB/04138/2020 and
618 UIDP/04138/2020. This study was in part supported by the NIH/NIAID under grant R01AI087520.
619 Francisco Martin was supported by FCT under PhD grant number SFRH/BD/87488/2012. CP is
620 funded by FCT under a contract-program as defined by DL No. 57/2016 and Law No. 57/2017.

621

622 **Authors' contributions**

623 Francisco Martin¹, José Maria Marcelino^{1,2}, Claudia Palladino¹, Inês Bárto¹, Susana Tracana¹,
624 Inês Moranguinho¹, Paloma Gonçalves¹, Rita Mateus¹, Rita Calado¹, Pedro Borrego¹, Thomas
625 Leitner³, Sofia Clemente⁴, Nuno Taveira^{1,2#}

626

627 NT and SC: conceived and designed the study. SC: provided the patients' data and specimens.
628 FM, JMM, IB, ST, IM, PG, RM, RC, PB, and TL: performed the experiments. FM, JMM, CP, TL and
629 NT: analyzed the data. FM, TL, and NT performed the statistical analysis. FM, TL and NT drafted
630 the manuscript and discussed the final version. All authors read and approved the final
631 manuscript.

632

633 **References**

- 634 1. Horwitz JA, *et al.* Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.
635 *Cell* **170**, 637-648 e610 (2017).
636
637 2. Rusert P, *et al.* Determinants of HIV-1 broadly neutralizing antibody induction. *Nat Med*
638 **22**, 1260-1267 (2016).
639
640 3. Landais E, *et al.* Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-
641 Saharan HIV Primary Infection Cohort. *PLoS Pathog* **12**, e1005369 (2016).
642
643 4. Hu X, *et al.* Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-
644 infected intravenous drug users naive to antiretroviral therapy. *Sci Rep* **7**, 46308 (2017).
645
646 5. Hraber P, *et al.* Impact of clade, geography, and age of the epidemic on HIV-1
647 neutralization by antibodies. *J Virol* **88**, 12623-12643 (2014).
648
649 6. Tomaras GD, *et al.* Polyclonal B cell responses to conserved neutralization epitopes in a
650 subset of HIV-1-infected individuals. *J Virol* **85**, 11502-11519 (2011).
651
652 7. Simek MD, *et al.* Human immunodeficiency virus type 1 elite neutralizers: individuals
653 with broad and potent neutralizing activity identified by using a high-throughput

- 654 neutralization assay together with an analytical selection algorithm. *J Virol* **83**, 7337-
655 7348 (2009).
- 656
- 657 8. Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and Broadly Neutralizing
658 Antibodies for HIV-1 Prevention. *Annu Rev Immunol* **38**, 673-703 (2020).
- 659
- 660 9. Walker LM, *et al.* Broad and potent neutralizing antibodies from an African donor reveal
661 a new HIV-1 vaccine target. *Science* **326**, 285-289 (2009).
- 662
- 663 10. Caskey M, *et al.* Viraemia suppressed in HIV-1-infected humans by broadly neutralizing
664 antibody 3BNC117. *Nature* **522**, 487-491 (2015).
- 665
- 666 11. Caskey M, *et al.* Corrigendum: Viraemia suppressed in HIV-1-infected humans by
667 broadly neutralizing antibody 3BNC117. *Nature*, (2016).
- 668
- 669 12. Caskey M, *et al.* Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. *Nat*
670 *Med* **23**, 185-191 (2017).
- 671
- 672 13. Schoofs T, *et al.* HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune
673 responses against HIV-1. *Science* **352**, 997-1001 (2016).
- 674
- 675 14. Scheid JF, *et al.* HIV-1 antibody 3BNC117 suppresses viral rebound in humans during
676 treatment interruption. *Nature* **535**, 556-560 (2016).
- 677
- 678 15. Nishimura Y, Martin MA. Of Mice, Macaques, and Men: Broadly Neutralizing Antibody
679 Immunotherapy for HIV-1. *Cell Host Microbe* **22**, 207-216 (2017).
- 680
- 681 16. Corey L, *et al.* Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1
682 Acquisition. *N Engl J Med* **384**, 1003-1014 (2021).
- 683
- 684 17. Spencer DA, Shapiro MB, Haigwood NL, Hessel AJ. Advancing HIV Broadly Neutralizing
685 Antibodies: From Discovery to the Clinic. *Front Public Health* **9**, 690017 (2021).
- 686
- 687 18. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection.
688 *Nat Immunol* **16**, 571-576 (2015).
- 689
- 690 19. Gray GE, *et al.* Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in
691 Adults. *N Engl J Med* **384**, 1089-1100 (2021).
- 692
- 693 20. Sanders RW, *et al.* A next-generation cleaved, soluble HIV-1 Env trimer, BG505
694 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-
695 neutralizing antibodies. *PLoS Pathog* **9**, e1003618 (2013).
- 696

- 697 21. Julien JP, *et al.* Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase
698 the arsenal of native-like Env immunogens. *Proc Natl Acad Sci U S A* **112**, 11947-11952
699 (2015).
- 700
- 701 22. Sanders RW, *et al.* HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like
702 envelope trimers. *Science* **349**, aac4223 (2015).
- 703
- 704 23. Pugach P, *et al.* A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. *J*
705 *Viro* **89**, 3380-3395 (2015).
- 706
- 707 24. Zhang P, *et al.* A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing
708 antibodies and reduces the risk of heterologous SHIV infection in macaques. *Nat Med*
709 **27**, 2234-2245 (2021).
- 710
- 711 25. Julg B, Barouch DH. Neutralizing antibodies for HIV-1 prevention. *Curr Opin HIV AIDS* **14**,
712 318-324 (2019).
- 713
- 714 26. Cohen YZ, Caskey M. Broadly neutralizing antibodies for treatment and prevention of
715 HIV-1 infection. *Curr Opin HIV AIDS* **13**, 366-373 (2018).
- 716
- 717 27. McGuire AT, Glenn JA, Lippy A, Stamatatos L. Diverse recombinant HIV-1 Envs fail to
718 activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-
719 HIV-1 antibodies PG9 and 447-52D. *J Virol* **88**, 2645-2657 (2014).
- 720
- 721 28. McGuire AT, *et al.* Specifically modified Env immunogens activate B-cell precursors of
722 broadly neutralizing HIV-1 antibodies in transgenic mice. *Nat Commun* **7**, 10618 (2016).
- 723
- 724 29. Hu Y, *et al.* Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected
725 Plasma Donor with Broadly Neutralizing Activity. *Vaccines (Basel)* **9**, (2021).
- 726
- 727 30. Kwong PD, Mascola JR. HIV-1 Vaccines Based on Antibody Identification, B Cell
728 Ontogeny, and Epitope Structure. *Immunity* **48**, 855-871 (2018).
- 729
- 730 31. Cizmeci D, *et al.* Distinct clonal evolution of B-cells in HIV controllers with neutralizing
731 antibody breadth. *Elife* **10**, (2021).
- 732
- 733 32. Bonsignori M, *et al.* Staged induction of HIV-1 glycan-dependent broadly neutralizing
734 antibodies. *Sci Transl Med* **9**, (2017).
- 735
- 736 33. Simonich CA, *et al.* HIV-1 Neutralizing Antibodies with Limited Hypermutation from an
737 Infant. *Cell* **166**, 77-87 (2016).
- 738

- 739 34. Anthony C, *et al.* Cooperation between Strain-Specific and Broadly Neutralizing
740 Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing
741 Epitope. *J Virol* **91**, (2017).
- 742
- 743 35. Martinez DR, *et al.* Maternal Binding and Neutralizing IgG Responses Targeting the C-
744 Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1
745 Transmission Risk. *J Virol* **91**, (2017).
- 746
- 747 36. Marcelino JM, *et al.* Resistance to antibody neutralization in HIV-2 infection occurs in
748 late stage disease and is associated with X4 tropism. *AIDS* **26**, 2275-2284 (2012).
- 749
- 750 37. Rocha C, *et al.* Evolution of the human immunodeficiency virus type 2 envelope in the
751 first years of infection is associated with the dynamics of the neutralizing antibody
752 response. *Retrovirology* **10**, 110 (2013).
- 753
- 754 38. Serra PA, Taveira N, Guedes RC. Computational Modulation of the V3 Region of
755 Glycoprotein gp125 of HIV-2. *Int J Mol Sci* **22**, (2021).
- 756
- 757 39. Gray ES, *et al.* Antibody specificities associated with neutralization breadth in plasma
758 from human immunodeficiency virus type 1 subtype C-infected blood donors. *J Virol* **83**,
759 8925-8937 (2009).
- 760
- 761 40. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum
762 neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F,
763 and I: lack of direct correlation between neutralization serotypes and genetic subtypes
764 and evidence for prevalent serum-dependent infectivity enhancement. *J Virol* **70**, 445-
765 458 (1996).
- 766
- 767 41. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of
768 human immunodeficiency virus type 1: genetic clades do not correspond to
769 neutralization serotypes but partially correspond to gp120 antigenic serotypes. *J Virol*
770 **70**, 427-444 (1996).
- 771
- 772 42. deCamp A, *et al.* Global panel of HIV-1 Env reference strains for standardized
773 assessments of vaccine-elicited neutralizing antibodies. *J Virol* **88**, 2489-2507 (2014).
- 774
- 775 43. Marcelino R, *et al.* Antibody response against selected epitopes in the HIV-1 envelope
776 gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients. *Sci Rep*
777 **11**, 8993 (2021).
- 778
- 779 44. Bartolo I, Calado R, Borrego P, Leitner T, Taveira N. Rare HIV-1 subtype J genomes and a
780 new H/U/CRF02_AG recombinant genome suggests an ancient origin of HIV-1 in Angola.
781 *AIDS Res Hum Retroviruses*, (2016).
- 782

- 783 45. Abecasis A, *et al.* HIV-1 genetic variants circulation in the North of Angola. *Infect Genet*
784 *Evol* **5**, 231-237 (2005).
- 785
786 46. Bartolo I, *et al.* HIV-1 diversity, transmission dynamics and primary drug resistance in
787 Angola. *PLoS One* **9**, e113626 (2014).
- 788
789 47. Bartolo I, *et al.* Highly divergent subtypes and new recombinant forms prevail in the
790 HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic. *Infect*
791 *Genet Evol* **9**, 672-682 (2009).
- 792
793 48. Pineda-Pena AC, *et al.* On the contribution of Angola to the initial spread of HIV-1. *Infect*
794 *Genet Evol* **46**, 219-222 (2016).
- 795
796 49. Faria NR, *et al.* HIV epidemiology. The early spread and epidemic ignition of HIV-1 in
797 human populations. *Science* **346**, 56-61 (2014).
- 798
799 50. Stefic K, Bouvin-Pley M, Braibant M, Barin F. Impact of HIV-1 Diversity on Its Sensitivity
800 to Neutralization. *Vaccines (Basel)* **7**, (2019).
- 801
802 51. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell
803 surface concentrations on infections by macrophagetropic isolates of human
804 immunodeficiency virus type 1. *J Virol* **72**, 2855-2864 (1998).
- 805
806 52. Bartolo I, *et al.* HIV-1 genetic diversity and transmitted drug resistance in health care
807 settings in Maputo, Mozambique. *J Acquir Immune Defic Syndr* **51**, 323-331 (2009).
- 808
809 53. Tamura K, Stecher G, Peterson D, Filipiński A, Kumar S. MEGA6: Molecular Evolutionary
810 Genetics Analysis version 6.0. *Mol Biol Evol* **30**, 2725-2729 (2013).
- 811
812 54. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution.
813 *Bioinformatics* **14**, 817-818 (1998).
- 814
815 55. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms
816 and methods to estimate maximum-likelihood phylogenies: assessing the performance
817 of PhyML 3.0. *Syst Biol* **59**, 307-321 (2010).
- 818
819 56. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV
820 coreceptor usage. *Nat Biotechnol* **25**, 1407-1410 (2007).
- 821
822 57. Vandekerckhove LP, *et al.* European guidelines on the clinical management of HIV-1
823 tropism testing. *Lancet Infect Dis* **11**, 394-407 (2011).
- 824

- 825 58. Weaver S, Shank SD, Spielman SJ, Li M, Muse SV, Kosakovsky Pond SL. Datamonkey 2.0:
826 A Modern Web Application for Characterizing Selective and Other Evolutionary
827 Processes. *Mol Biol Evol* **35**, 773-777 (2018).
- 828
829 59. Kosakovsky Pond SL, Frost SD. Not so different after all: a comparison of methods for
830 detecting amino acid sites under selection. *Mol Biol Evol* **22**, 1208-1222 (2005).
- 831
832 60. Zhang M, *et al.* Tracking global patterns of N-linked glycosylation site variation in highly
833 variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
834 *Glycobiology* **14**, 1229-1246 (2004).
- 835
836 61. Calado R, *et al.* A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing
837 Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2
838 HIV-1 Neutralizing Antibodies. *Vaccines (Basel)* **8**, (2020).
- 839
840 62. Mascola JR, *et al.* Recommendations for the design and use of standard virus panels to
841 assess neutralizing antibody responses elicited by candidate human immunodeficiency
842 virus type 1 vaccines. *J Virol* **79**, 10103-10107 (2005).
- 843
844 63. Mishra N, *et al.* Broadly neutralizing plasma antibodies effective against autologous
845 circulating viruses in infants with multivariant HIV-1 infection. *Nat Commun* **11**, 4409
846 (2020).
- 847
848 64. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using
849 Principal Component Analysis and heatmap. *Nucleic Acids Res* **43**, W566-570 (2015).
- 850
851 65. Firth HV, *et al.* DECIPHER: Database of Chromosomal Imbalance and Phenotype in
852 Humans Using Ensembl Resources. *Am J Hum Genet* **84**, 524-533 (2009).
- 853
854 66. R, Core, Team. R: A language and environment for statistical computing. (2017).
- 855
856 67. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag (2016).
- 857
858 68. Mellors JW, *et al.* Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-
859 1 infection. *Ann Intern Med* **126**, 946-954 (1997).
- 860
861 69. Walker LM, *et al.* Broad neutralization coverage of HIV by multiple highly potent
862 antibodies. *Nature* **477**, 466-470 (2011).
- 863
864 70. Trkola A, *et al.* Human monoclonal antibody 2G12 defines a distinctive neutralization
865 epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. *J Virol* **70**,
866 1100-1108 (1996).
- 867

- 868 71. Brunel FM, *et al.* Structure-function analysis of the epitope for 4E10, a broadly
869 neutralizing human immunodeficiency virus type 1 antibody. *J Virol* **80**, 1680-1687
870 (2006).
- 871
- 872 72. Barroso H, *et al.* Evolutionary and structural features of the C2, V3 and C3 envelope
873 regions underlying the differences in HIV-1 and HIV-2 biology and infection. *PLoS One* **6**,
874 e14548 (2011).
- 875
- 876 73. Mabvakure BM, *et al.* Positive Selection at Key Residues in the HIV Envelope
877 Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. *J Virol* **93**,
878 (2019).
- 879
- 880 74. Dingens AS, Arenz D, Weight H, Overbaugh J, Bloom JD. An Antigenic Atlas of HIV-1
881 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural
882 Epitopes. *Immunity* **50**, 520-532 e523 (2019).
- 883
- 884 75. Landais E, Moore PL. Development of broadly neutralizing antibodies in HIV-1 infected
885 elite neutralizers. *Retrovirology* **15**, 61 (2018).
- 886
- 887 76. Bricault CA, *et al.* HIV-1 Neutralizing Antibody Signatures and Application to Epitope-
888 Targeted Vaccine Design. *Cell Host Microbe* **26**, 296 (2019).
- 889
- 890 77. Local, Burden, of, Disease, HIV, Collaborators. Subnational mapping of HIV incidence and
891 mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a
892 modelling study. *Lancet HIV* **8**, e363-e375 (2021).
- 893
- 894 78. Sebastiao CS, Morais J, Brito M. Factors Influencing HIV Drug Resistance among Pregnant
895 Women in Luanda, Angola: Findings from a Cross-Sectional Study. *Trop Med Infect Dis*
896 **6**, (2021).
- 897
- 898 79. Gray ES, *et al.* The neutralization breadth of HIV-1 develops incrementally over four
899 years and is associated with CD4+ T cell decline and high viral load during acute
900 infection. *J Virol* **85**, 4828-4840 (2011).
- 901
- 902 80. Moore PL. The Neutralizing Antibody Response to the HIV-1 Env Protein. *Curr HIV Res*
903 **16**, 21-28 (2018).
- 904
- 905 81. Bhiman JN, *et al.* Viral variants that initiate and drive maturation of V1V2-directed HIV-
906 1 broadly neutralizing antibodies. *Nat Med* **21**, 1332-1336 (2015).
- 907
- 908 82. Liao HX, *et al.* Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
909 *Nature* **496**, 469-476 (2013).
- 910

- 911 83. Doria-Rose NA, *et al.* Developmental pathway for potent V1V2-directed HIV-neutralizing
912 antibodies. *Nature* **509**, 55-62 (2014).
- 913
- 914 84. Ndlovu B, *et al.* Envelope characteristics in individuals who developed neutralizing
915 antibodies targeting different epitopes in HIV-1 subtype C infection. *Virology* **546**, 1-12
916 (2020).
- 917
- 918 85. Beirnaert E, *et al.* Identification and characterization of sera from HIV-infected
919 individuals with broad cross-neutralizing activity against group M (env clade A-H) and
920 group O primary HIV-1 isolates. *J Med Virol* **62**, 14-24 (2000).
- 921
- 922 86. Kouyos RD, *et al.* Tracing HIV-1 strains that imprint broadly neutralizing antibody
923 responses. *Nature* **561**, 406-410 (2018).
- 924
- 925 87. Sather DN, *et al.* Factors associated with the development of cross-reactive neutralizing
926 antibodies during human immunodeficiency virus type 1 infection. *J Virol* **83**, 757-769
927 (2009).
- 928
- 929 88. Moir S, Fauci AS. B-cell responses to HIV infection. *Immunol Rev* **275**, 33-48 (2017).
- 930
- 931 89. Badura R, *et al.* Early ART in Acute HIV-1 Infection: Impact on the B-Cell Compartment.
932 *Front Cell Infect Microbiol* **10**, 347 (2020).
- 933
- 934 90. Moir S, *et al.* B cells in early and chronic HIV infection: evidence for preservation of
935 immune function associated with early initiation of antiretroviral therapy. *Blood* **116**,
936 5571-5579 (2010).
- 937
- 938 91. Gach JS, *et al.* HIV-1 specific antibody titers and neutralization among chronically
939 infected patients on long-term suppressive antiretroviral therapy (ART): a cross-
940 sectional study. *PLoS One* **9**, e85371 (2014).
- 941
- 942 92. Kong R, *et al.* Broad and potent neutralizing antibody responses elicited in natural HIV-
943 2 infection. *J Virol* **86**, 947-960 (2012).
- 944
- 945 93. Rodriguez SK, *et al.* Comparison of heterologous neutralizing antibody responses of
946 human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients:
947 distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. *J Virol*
948 **81**, 5331-5338 (2007).
- 949
- 950 94. Rocha C, *et al.* Potency of HIV-2-specific antibodies increase in direct association with
951 loss of memory B cells. *AIDS* **31**, 2431-2433 (2017).
- 952

- 953 95. Bai H, Li Y, Michael NL, Robb ML, Rolland M. The breadth of HIV-1 neutralizing antibodies
954 depends on the conservation of key sites in their epitopes. *PLoS Comput Biol* **15**,
955 e1007056 (2019).
- 956
957 96. Rademeyer C, *et al.* Genetic characteristics of HIV-1 subtype C envelopes inducing cross-
958 neutralizing antibodies. *Virology* **368**, 172-181 (2007).
- 959
960 97. Kumar S, *et al.* An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric
961 Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving
962 Viruses. *J Virol* **93**, (2019).
- 963
964 98. Cheedarla N, *et al.* Evolution of Neutralization Response in HIV-1 Subtype C-Infected
965 Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains. *Front Immunol*
966 **9**, 618 (2018).
- 967
968 99. Lei L, *et al.* The HIV-1 Envelope Glycoprotein C3/V4 Region Defines a Prevalent
969 Neutralization Epitope following Immunization. *Cell Rep* **27**, 586-598 e586 (2019).
- 970
971